Combination of pazopanib and paclitaxel safe in urothelial cancer

Share :
Published: 26 Feb 2015
Views: 2785
Rating:
Save
Prof Sandy Srinivas - Stanford University Medical Centre, Stanford, USA

Prof Srinivas talks to ecancertv at ASCO GU 2015 about the results of a phase II study which looked at the use of pazopanib with weekly paclitaxel in refractory urothelial cancer.